YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and$238.6 million in FY 2024, up 10% and 8%, respectively, compared with 20231 FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion, up 26$50 million milestone to Theravance Biopharma2,3 CYPRESS study on track to enroll final patient in the open label portion by mid-2025 Ended Q4 2024 with $88 million in cash, excluding the$50 million TRELEGY mi ...